Atlantic Therapeutics

Our vision is to enable millions of people each year to restore their pelvic floor, and thereby restore their control, confidence and active lifestyle.

We manufacture innovative pelvic floor muscle strengthening and nerve stimulation products of medical device quality, supported by strong clinical evidence and subjected to controlled product trials. We are at the leading edge of technological developments in muscle rehabilitation and conditioning and are pioneering clinically proven pelvic floor health solutions. Thousands of clinicians and customers rely on Atlantic Therapeutics products such as INNOVO® (www.restorethefloor.com) every day, and our products improve many thousands of lives every year. We continue to carry out rigorous clinical trials to support the use of Innovotherapy to treat bladder weakness.

Since launching in March 2016, Innovotherapy has become the leading choice for a safe, effective, home-based treatment for the causes, not just the symptoms, of bladder weakness. Innovotherapy is already available in the UK, France, Germany, Ireland and the Middle East with further launches planned in the near future.

Atlantic Therapeutics’ offices are located in Galway, on the Atlantic coast of Ireland, London, Paris and Salem, close to Lake Constance in Germany.

What is Innovotherapy?

INNOVO® is the only non-invasive pelvic floor exerciser that treats the root cause of bladder weakness – a weak pelvic floor, rather than just managing the symptoms. INNOVO®’s unique Multipath technology uses electrical muscle stimulation (EMS) to deliver 180 perfect and complete pelvic floor contractions to the entire network of pelvic floor muscles in every 30 minute session. It is a proven technology designed to optimally strengthen the pelvic floor and re-educate the muscles that control bladder function.

The new & improved INNOVO® is super simple to use, just pull it on like a pair of cycling shorts and let INNOVO® do the hard work for you. A hand-held controller connects to the shorts and allows the user to increase the intensity of the stimulations - feel your entire pelvic floor lifting & releasing!

INNOVO® treats Stress, Urge & Mixed Incontinence in both women and men, and is used in the comfort of your home. Best of all, INNOVO® is clinically proven to work, with results in as little as 4 weeks!1

 

93%

of users saw a significant improvement after 4 weeks1

86%

of users saw were defined as dry or near dry after 12 weeks1

90%

of users would recommend the therapy to others2

Who is affected by bladder weakness?

Atlantic Therapeutics appoints Chairman

26th July 2017 - Atlantic Therapeutics is delighted to announce the appointment of new Chairman Gordie Nye.

Read more

A non-invasive, clinically proven therapy

Distributors

Atlantic Therapeutics is proud to work with knowledgeable, driven partners to give us the best possible understanding of local market needs and to provide our customers with the highest possible level of service.

For information about how you can access Innovotherapy in your country, please contact us.

If you are interested in joining Atlantic Therapeutics’ distribution network as we introduce our clinically proven, safe and effective treatment globally, please contact us through info@atlantictherapeutics.com.

Ambassadors

We know that bladder weakness is a difficult subject to bring up, so at Atlantic Therapeutics we’re keen to support and reward ambassadors who are open to discussing and promoting a clinically proven solution that will help to improve their customers’ quality of life. Contact us today to find out how you can join Atlantic Therapeutics growing network of Innovotherapy Ambassadors.

Corporate Information

Atlantic Therapeutics develops professional and consumer medical devices, related software, apps and connected health technologies to treat all types of incontinence, sexual health dysfunctions, and other associated disorders by strengthening muscles and modulating nerves of the pelvic floor. All Atlantic Therapeutics Group Ltd. products are certified under the European Medical Devices Directive 93/42/EEC.

Atlantic Therapeutics Group Ltd, has recently successfully completed a €15 million growth capital financing, enabling the company to move forward with the next phase of growth and treat millions of people across the globe who suffer from bladder weakness, clinically known as stress urinary incontinence. 

The funds come from a combination of venture capital investment from Seroba Life Sciences and Earlybird Venture Capital, as well as Bio-medical Research Group Ltd (previous owner) which retains a minority shareholding. The capital enables Atlantic Therapeutics to accelerate growth from INNOVO® technology platform via market and geographic expansion and new product development. 

Board of Directors

Mr Gordie Nye, Chairman of the Board

Mr Steve Atkinson, Chief Executive Officer

Mr Padraic Clarke, Chief Financial Officer

Dr Daniel O’Mahony, Partner with Seroba Life Science

Thom Rasche, Partner at Earlybird

Dr Bernard Collins, Chairman of Biomedical Research

Medical Advisory Board Members

Professor François Haab is a world leading urologist practicing in Urologie Paris Opéra and was previously Director of Urology at Hôpital Tenon (Assistance Publique)

Professor Ralf Tunn is Head of the Department of Urogynecology in Berlin and coordinator of the “Deutsches Beckenbodenzentrum” (German Pelvic Floor Centres)

Professor Linda Cardozo is an internationally recognised key opinion leader, Professor of Urogynaecology and Consultant Gynaecologist at King’s College Hospital, London

Prof Roger R Dmochowski is Professor at the Department of Urology and Director of the Section of Female Pelvic Medicine at Vanderbilt University in Nashville

Non-Medical Advisor: David Kaysen is ex-CEO of Uroplasty, Diametrics Medical and Compex Technologies and is on the board of Cefaly. Dave has extensive experience in the clinical application and commercialization of neuromodulation therapies.

Contact Us